Xencor (XNCR) Assets Average (2014 - 2026)
Xencor (XNCR) posted quarterly Assets Average of $806.2 million for Q1 2026, down 13.16% year-over-year from $928.3 million in Q1 2025, and down 7.57% quarter-over-quarter from $872.2 million in Q4 2025.
Xencor (XNCR) Assets Average (2014 - 2026) Analysis & Trends
Xencor (XNCR) has reported Assets Average for 13 consecutive years, with $806.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 13.16% year-over-year to $806.2 million; the TTM figure through Mar 2026 stood at $806.2 million (down 13.16% YoY), while the FY2025 annual figure was $913.7 million, down 4.68% from the prior year.
- Assets Average fell to $806.2 million in Q1 2026 per XNCR's latest filing, from $872.2 million in the prior quarter.
- Across five years, Assets Average topped out at $975.9 million in Q4 2024 and bottomed at $778.3 million in Q3 2023.
- Historically, Assets Average has averaged $865.9 million across 5 years, with a median of $868.7 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average gained 23.11% — and 2026, when it decreased 13.16%.
- Xencor's Assets Average stood at $840.8 million in 2022, then increased by 3.69% to $871.8 million in 2023, then gained by 11.95% to $975.9 million in 2024, then dropped by 10.63% to $872.2 million in 2025, then declined by 7.57% to $806.2 million in 2026.
- Business Quant data shows XNCR's Assets Average at $806.2 million in Q1 2026, $872.2 million in Q4 2025, and $874.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 730.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 730.90 Mn |
| Mar 31, 2026 | 806.17 Mn |
| Dec 31, 2025 | 872.15 Mn |
| Sep 30, 2025 | 874.12 Mn |
| Jun 30, 2025 | 892.06 Mn |
| Mar 31, 2025 | 928.32 Mn |
| Dec 31, 2024 | 975.92 Mn |
| Sep 30, 2024 | 920.26 Mn |
| Jun 30, 2024 | 868.73 Mn |
| Mar 31, 2024 | 930.99 Mn |
| Dec 31, 2023 | 871.78 Mn |
| Sep 30, 2023 | 778.28 Mn |
| Jun 30, 2023 | 790.77 Mn |
| Mar 31, 2023 | 824.84 Mn |
| Dec 31, 2022 | 840.77 Mn |
| Sep 30, 2022 | 843.30 Mn |
| Jun 30, 2022 | 854.62 Mn |
| Mar 31, 2022 | 848.07 Mn |
| Dec 31, 2021 | 767.74 Mn |
| Sep 30, 2021 | 696.43 Mn |